{"id":"W4412647773","doi":"10.1016/j.eururo.2025.05.019","title":"First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Lenvatinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Immunotherapy; Cancer; Sorafenib; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000576156,0.0004890647,0.0007421137,0.0001548585,0.0003022703,0.00003644031,0.0004923895,0.0001607042,0.0001425045],"category_scores_gemma":[0.0004557612,0.0003544277,0.0003426368,0.0003130645,0.0001996352,0.00005763141,0.0002430766,0.0005740872,0.0002865558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001772139,"about_ca_system_score_gemma":0.0003127614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000133484,"about_ca_topic_score_gemma":0.00003944379,"domain_scores_codex":[0.9964631,0.000537498,0.001012949,0.00103986,0.0002665342,0.0006800867],"domain_scores_gemma":[0.9967684,0.00114012,0.0003801538,0.001312362,0.0001964283,0.0002025901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8819804,0.002250173,0.0001909338,0.00009790551,0.0002818774,0.001524722,0.001219101,0.001362961,0.03163926,0.00006458748,0.07451096,0.004877091],"study_design_scores_gemma":[0.6998912,0.0191345,0.006256038,0.00003999687,0.00129504,0.0000330517,0.0001017556,0.004703123,0.0315064,0.00008991006,0.2364722,0.0004767478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9436529,0.0008218518,0.001503693,0.0053136,0.00091287,0.002769395,0.000403735,0.0001372885,0.04448472],"genre_scores_gemma":[0.9823817,0.00004760109,0.000852389,0.002669871,0.0009314245,0.00008463148,0.001679319,0.000109591,0.01124347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1820892,"threshold_uncertainty_score":0.9998907,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02573848624349531,"score_gpt":0.2798555129792575,"score_spread":0.2541170267357622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}